Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 3153-3156

  Kruit, Adrian ^a,b   Reyes Moreno, Carlos ^a   Newling, Donald W W ^b   Geldof, Albert ^b   Koutsilieris, Michael ^a,c  

^a Université Laval   (Canada)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Combination therapy; Doxorubicin; Glucocorticoids; Irradiation; Prostate cancer cells

Indexed keywords

DEXAMETHASONE; DNA FRAGMENT; DOXORUBICIN; GLUCOCORTICOID;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

CELL CYCLE; DEXAMETHASONE; DOXORUBICIN; GAMMA RAYS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033428326     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Isaacs JT: Antagonistic effect of androgen on prostatic cell death. Prostate 5: 545-557, 1984.
2. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50: 3748-3753, 1990.
3. Koutsilieris M: Skeletal metastasis in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 18: 51-64, 1995.
4. Scher HI, Steineck G, Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142-148, 1995.
5. Newling DW: The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemother Pharmacol 30: 90-94, 1992.
6. Kubota Y, Nakada T, Imai K, Yamanaka H, Sakai H, Saito Y, Tomaru Y, Kitamura K, Sugano O, Sasagawa I: Chemo-endocrine therapy in patients with stage D2 prostate cancer. Prostate 26: 1, 50-54, 1995.
7. Coughlin CT, Richmond RC, Page RL: Platinum drug delivery and radiation for locally advanced prostate cancer. Int J Radiation Biol Phys 28: 1029-1038, 1994.
8. Geldof M, Slotman BJ: Radiosensltizing effect of cisplatin in prostate cancer cell lines. Cancer Letters 101: 233-239, 1996.
9. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76: 96-100, 1995.
10. Koutsilieris M, Dimopoulos MA, Doillon C, Sourla A, Reyes-Moreno C, Choki I: The molecular concept of prostate cancer. Cancer J 9: 89-94, 1996.
11. Abraham A, Shim H, Wehrle JP, Glickson JD: Inhibition of tumor cell proliferation by dexamethasone: 31P NMR studies of RIF-1 fibrosarcoma cells perfused in vitro. NMR Biomed 9: 173-178, 1996.
12. Takenawa J, Kaneko Y, Okumura K, Yoshiba O, Nakayama H, Fujita J: Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J Urol 153: 858-62, 1995.
13. Koutsilieris M, Grondin F, Lehoux, JG: The expression of mRNA for glucocorticoid receptor gene and functional glucocorticoid receptors detected in PA-III rat prostate adenocarcinoma cells. Anticancer Res 12: 899-904, 1992.
14. Reyes-Moreno CR, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M: Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 26: 260-269, 1995.
15. Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M: Osteoblast derived survival factors can rescue PC-3 human prostate cancer cells from adriamycin-apoptosis, in vitro. Urology 52: 341-347, 1998.
16. Pollack A, Ciancio G: Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation. In: Flow Cytometry (Darzynkiewicz Z and Crissman HA. eds). San Diego Academic Press 1995, pp 19-24.
17. Geldof M, Kruit A, Newling DWW, Slotman BJ: Synergism between cisplatin and radiotherapy in an in vitro tumor cell line. Anticancer Res 19: in press, 1999.
18. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 32: 1-13, 1994.
19. Han Z, Chatterjee D, He DM, Early J, Pantazis P, Wycke JH, Hendrickson EA: Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol Cell Biol 15: 5849-5857, 1995.
20. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, Weichselbaum RR: Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 46: 31-36, 1991.
21. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
22. Millar BC, Jenkins TC, Fielden EM, Jinks S: Polyfunctional radiosensitizers VI. Dexamethasone inhibits shoulder modification by uncharged nitroxyl biradicals in mammalian cells irradiated in vitro. Radiat Res 96: 160-172, 1983.
23. Brock WA, Williams M, McNaney D, Milas L, Peters LJ, Weischelbaum RR: Modification by dexamethasone of radiation response of in vitro cultured cells. Int J Radiat Biol Phys 10: 2113-2117, 1984.
24. Leith JT: In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate 24: 119-124, 1994.
25. Millar BC, Jinks S: Studies on the relationship between the radiation and glutathione content of human and rodent cells after treatment with dexamethasone in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 47: 539-552, 1985.